SEC Form 4 · accession 0001325812-17-000035

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Dec 19, 2017

Accepted (ET)

Dec 21, 2017 · 4:36 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Dec 19, 2017	M	1,587	$63.00	A	151,297	D
Common Stock^F1	holding	—	—		—	2,960	I	by Managed Account

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Performance Based Stock Option 2016 (right to buy)	$42.22	Dec 20, 2017	A	6,250	A	Dec 20, 2017	Dec 20, 2026	Common Stock	6,250	6,250	D
Stock Option (right to buy)^F3	$63.00	Dec 19, 2017	M	1,587	A	—	Dec 18, 2023	Common Stock	1,587	148,413	D

F1The reporting person owns 2,960 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F2On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective December 20, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares.
F3The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter